Electro-Optical Sciences Announces MelaFind(R) Development Update
Electro-Optical Sciences, Inc. (”EOS”) (NASDAQ: MELA), announced that the blinded pivotal trial of MelaFind(R), a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma, is over two-thirds complete. Six pivotal trial study sites are currently active, and an additional seventh and final site is expected to be activated in the upcoming weeks.
More: continued here
Filed under: Cancer on January 9th, 2008